Literature DB >> 21453239

Inhibition of hyaluronan synthase-3 decreases subcutaneous colon cancer growth by increasing apoptosis.

Brian P Teng1, Melissa D Heffler, Eric C Lai, Ya-Li Zhao, Charles M LeVea, Vita M Golubovskaya, Kelli M Bullarddunn.   

Abstract

Hyaluronan (HA) and hyaluronan synthases (HAS) have been implicated in cancer growth and progression. We previously have shown that HAS3 and HA mediate tumor growth in SW620 colon cancer cells, but the mechanism remains poorly understood. In addition, the effect of HAS3 inhibition on tumor growth with other cells lines has not been explored. We therefore hypothesized that inhibition of HAS3 in highly tumorigenic HCT116 colon cancer cells would decrease tumor growth and that the underlying mechanism would involve altering proliferation and/or apoptosis. HAS3 expression was inhibited by transfection with siRNA; a scrambled sequence served as a control. Stable transfectants were injected into the flanks of nude mice and tumor growth followed for 30 days. Proliferation and apoptosis were then assessed in the harvested tumors. Results were compared using the Students' t-test and ANOVA where appropriate. siRNA transfection decreased HAS3 expression, protein production, and pericellular HA retention, and decreased in vivo tumor growth. Proliferation was unaffected in the HCT116 tumors, but increased slightly in the SW620 tumors. In contrast, HAS3 inhibition significantly increased apoptosis in all tumors. HAS3 inhibition decreases subcutaneous tumor growth by colon cancer cells and significantly increases apoptosis with less effect on proliferation. These data show that HAS3 and HA mediate colon cancer growth by inhibiting apoptosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453239      PMCID: PMC3265824          DOI: 10.2174/187152011796817655

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  49 in total

1.  Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer.

Authors:  Alessandro Lugli; Inti Zlobec; Ursula Günthert; Parham Minoo; Kristi Baker; Luigi Tornillo; Luigi Terracciano; Jeremy R Jass
Journal:  Mod Pathol       Date:  2006-06-09       Impact factor: 7.842

2.  Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells.

Authors:  Melanie A Simpson; Christopher M Wilson; Leo T Furcht; Andrew P Spicer; Theodore R Oegema; James B McCarthy
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

3.  Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells.

Authors:  N Itano; T Sawai; O Miyaishi; K Kimata
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

4.  Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.

Authors:  K Ropponen; M Tammi; J Parkkinen; M Eskelinen; R Tammi; P Lipponen; U Agren; E Alhava; V M Kosma
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

5.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.

Authors:  Bryan P Toole
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

6.  Characterization of the recombinant rat 175-kDa hyaluronan receptor for endocytosis (HARE).

Authors:  Janet A Weigel; Paul H Weigel
Journal:  J Biol Chem       Date:  2003-08-20       Impact factor: 5.157

7.  Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response.

Authors:  Laura Alaniz; Miguel Rizzo; Mariana Malvicini; Jorge Jaunarena; Diego Avella; Catalina Atorrasagasti; Jorge B Aquino; Mariana Garcia; Pablo Matar; Marcelo Silva; Guilermo Mazzolini
Journal:  Cancer Lett       Date:  2009-01-29       Impact factor: 8.679

8.  Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway.

Authors:  Shibnath Ghatak; Suniti Misra; Bryan P Toole
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

9.  Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas.

Authors:  R Kopp; M Fichter; G Schalhorn; J Danescu; S Classen
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

10.  Two-marker protein profile predicts poor prognosis in patients with early rectal cancer.

Authors:  I Zlobec; K Baker; L Terracciano; S Peter; L Degen; C Beglinger; A Lugli
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

View more
  11 in total

1.  Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Authors:  Baotran Ho; Gretchen Olson; Sheila Figel; Irwin Gelman; William G Cance; Vita M Golubovskaya
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

2.  HAS3 underexpression as an indicator of poor prognosis in patients with urothelial carcinoma of the upper urinary tract and urinary bladder.

Authors:  I-Wei Chang; Peir-In Liang; Ching-Chia Li; Wen-Jeng Wu; Chun-Nung Huang; Victor Chia-Hsiang Lin; Chao-Tien Hsu; Hong-Lin He; Ting-Feng Wu; Chih-Hsin Hung; Chien-Feng Li
Journal:  Tumour Biol       Date:  2015-05-02

3.  Molecular characterization of kidney cancer: association of hyaluronic acid family with histological subtypes and metastasis.

Authors:  Andrew Chi; Samir P Shirodkar; Diogo O Escudero; Obi O Ekwenna; Travis J Yates; Rajinikanth Ayyathurai; Michael Garcia-Roig; Jeffrey C Gahan; Murugesan Manoharan; Vincent G Bird; Vinata B Lokeshwar
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

4.  FAK and HAS inhibition synergistically decrease colon cancer cell viability and affect expression of critical genes.

Authors:  Melissa Heffler; Vita M Golubovskaya; Jeffrey Conroy; Song Liu; Dan Wang; William G Cance; Kelli B Dunn
Journal:  Anticancer Agents Med Chem       Date:  2013-05       Impact factor: 2.505

5.  Rab10-mediated endocytosis of the hyaluronan synthase HAS3 regulates hyaluronan synthesis and cell adhesion to collagen.

Authors:  Ashik Jawahar Deen; Kirsi Rilla; Sanna Oikari; Riikka Kärnä; Genevieve Bart; Jukka Häyrinen; Avinash Rahul Bathina; Antti Ropponen; Katri Makkonen; Raija H Tammi; Markku I Tammi
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

6.  Esophageal Squamous Cell Carcinoma Cells Modulate Chemokine Expression and Hyaluronan Synthesis in Fibroblasts.

Authors:  Inga Kretschmer; Till Freudenberger; Sören Twarock; Yu Yamaguchi; Maria Grandoch; Jens W Fischer
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

Review 7.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

8.  A novel 8-gene panel for prediction of early biochemical recurrence in patients with prostate cancer after radical prostatectomy.

Authors:  Jinan Guo; Chenhui Zhao; Xinzhou Zhang; Zhong Wan; Tingting Chen; Jiashun Miao; Jinping Cai; Wenchuan Xie; Hao Chen; Mengli Huang; Xiaochen Zhao; Wei Wei; Qi Shen
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

9.  Accumulation of extracellular hyaluronan by hyaluronan synthase 3 promotes tumor growth and modulates the pancreatic cancer microenvironment.

Authors:  Anne Kultti; Chunmei Zhao; Netai C Singha; Susan Zimmerman; Ryan J Osgood; Rebecca Symons; Ping Jiang; Xiaoming Li; Curtis B Thompson; Jeffrey R Infante; Michael A Jacobetz; David A Tuveson; Gregory I Frost; H Michael Shepard; Zhongdong Huang
Journal:  Biomed Res Int       Date:  2014-07-24       Impact factor: 3.411

10.  Lysine-specific demethylase 1 (LSD1/KDM1A) contributes to colorectal tumorigenesis via activation of the Wnt/β-catenin pathway by down-regulating Dickkopf-1 (DKK1) [corrected].

Authors:  Zebin Huang; Shangze Li; Wei Song; Xin Li; Qinshan Li; Zeyan Zhang; Yongqing Han; Xiaodong Zhang; Shiying Miao; Runlei Du; Linfang Wang
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.